Porton(SZ:300363)2024-10-27 17:24Group 1: Capacity Utilization and Production - The capacity utilization rate for small molecule CDMO is approximately 60%, with higher rates at the Chongqing and Jiangxi production bases [1] - The Hubei Yuyang production base is still in the enhancement process, and differentiated product classification is being used to improve capacity utilization [2] - The Shanghai Fengxian site will undertake new sub-type projects, which will help improve capacity utilization [2] Group 2: Orders and Revenue Performance - In the first three quarters of the year, orders and revenue have shown good performance, driven by both enhanced core competitiveness and recovering industry demand [2] - The company has seen a 40% growth in orders for small molecule APIs CDMO business, with growth primarily from the European and American markets [3] Group 3: Profitability and Cost Management - The gross margin has continued to improve quarter-on-quarter, driven by effective cost control and a favorable product mix in the European and American markets [3] - The company aims to continue seeking business improvements in 2025, focusing on cost reduction and efficiency [4] Group 4: Market Trends and Strategic Focus - The biotech market is recovering, with financing trends favoring leading companies, and new biotech teams emerging in various fields [3] - The company plans to enhance its market share in the U.S. biotech sector and continuously track and develop high-value clients and pipelines [5] Group 5: Collaboration and Client Preferences - The collaboration model with Yinos is based on leveraging both companies' strengths to provide integrated delivery services, particularly for biotech clients [3] - Overseas clients are increasingly focused on service quality and rapid delivery, with a growing demand for integrated API and formulation solutions [5] Group 6: Future Plans and Investments - The company maintains an open attitude towards potential mergers and acquisitions based on business needs [5] - Significant CAPEX investments are planned for the Slovenian base, with ongoing recruitment efforts to enhance workforce efficiency [5]